From: Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
Characteristics | Placebo group (N = 37) | Ganciclovir group (N = 39) |
---|---|---|
Age, y | 67.0 (59.0–72.0) | 63.0 (54.0–71.0) |
Male sex, no. (%) | 25 (67.6) | 31 (79.5) |
Body mass index, kg/m2a | 27.7 (21.3–31.2) | 26.2 (23.6–35.2) |
McCabe score = 1 (non-fatal), no. (%) | 32 (86.5) | 28 (71.8) |
Preexisting disease, no. (%) | ||
NYHA III/IV | 4 (10.8) | 3 (7.7) |
Cancer/hemopathy | 3 (8.1) | 7 (17.9) |
Diabetes mellitus | 6 (16.2) | 10 (25.6) |
COPD | 4 (10.8) | 7 (17.9) |
Cirrhosis | 3 (8.1) | 0 (0) |
Chronic renal failure a | 1 (2.7) | 2 (5.1) |
Alcoholism, no. (%) | 6 (16.2) | 5 (12.8) |
Recent transfusion (< 1 month), no. (%) | 12 (32.4) | 13 (33.3) |
Corticosteroids (< 1 month), no. (%) | 5 (13.5) | 1 (2.6) |
No preexisting disease and no risk factor, no. (%) | 17 (45.9) | 16 (41) |
Admission category, no. (%) | ||
Medical | 31 (83.8) | 34 (87.2) |
Emergency surgery | 2 (5.4) | 4 (10.3) |
Planned surgery | 4 (10.8) | 1 (2.8) |
Primary reason for mechanical ventilation, no. (%) | ||
Acute respiratory failure | 13 (35.1) | 12 (30.8) |
Septic shock | 8 (21.6) | 8 (20.5) |
Cardiogenic shock | 2 (5.4) | 5 (12.8) |
Post-operative acute respiratory failure | 4 (10.8) | 1 (2.6) |
Exacerbation of chronic respiratory disease | 0 (0) | 4 (10.3) |
Trauma | 1 (2.7) | 0 (0) |
Neurologic | 1 (2.7) | 1 (2.6) |
Cardiac arrest | 1 (2.7) | 0 (0) |
Others | 7 (18.9) | 8 (20.5) |
SAPS II | 45.0 (38.5–56.5) | 45.0 (37.0–59.0) |
SOFA score | 10 (8–15) | 9 (7–10) |
Organ/system failure, no. (%)b | ||
Cardiovascular | 23 (62.2) | 28 (71.8) |
Respiratory | 26 (81.2) | 29 (80.6) |
Renal | 11 (29.7) | 11 (28.2) |
Central nervous | 8 (21.6) | 1 (2.6) |
Hepatic | 1 (2.8) | 2 (5.3) |
Coagulation | 4 (10.8) | 2 (5.1) |